Sign inJoin waitlistJoin the waitlist

Vivek Subbiah

Professor-Univ Med Line · Stanford Health Care

Credentials: · · · · · ·

History

Stanford Health Care
Present
Stanford Health Care
Present
University of Texas M D Anderson Cancer Center
Present

UT MD Anderson Cancer Center Hematology and Oncology Fellowship (2011) TX
2008–2011
Internal Medicine
The MetroHealth System/Case Western Reserve University
2005–2008

Research

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
New England Journal of Medicine · 2015 · 1,432 citations
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Journal of Clinical Oncology · 2018 · First of 14 authors · 704 citations
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2020 · 650 citations

David Hong
116 papers
Funda Meric-Bernstam
110 papers
Sarina Piha-Paul
99 papers
FJ
Filip Janku
96 papers
Aung Naing
95 papers
Siqing Fu
91 papers
Razelle Kurzrock
79 papers
Apostolia Tsimberidou
78 papers
DK
Daniel Karp
72 papers
Jordi Ahnert
38 papers · 13 as a fellow
RZ
Ralph Zinner
32 papers
Shubham Pant
31 papers

Grants

Discovery of the Next-Generation RET-Targeted Drugs Based on Nicotinamide Scaffold
National Cancer Institute · R01
PI · $612.1K · University of Oklahoma Hlth Sciences Ctr
2022–2027
Blocking Tumor Progression in Therapy-Responsive RET Aberration-Associated Cancer
National Cancer Institute · R01
PI · $1.2M · University of Oklahoma Hlth Sciences Ctr
2020–2025

Clinical trials

The Registry of Oncology Outcomes Associated With Testing and Treatment
Principal investigator · Completed
Taproot Health
2021–2024
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Principal investigator · Recruiting
TargetCancer Foundation
2020–2028
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
Principal investigator · Terminated · Phase 1, Phase 2
MultiVir, Inc.
2018–2020
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2018–2022